Antiplatelet and Anticoagulation Therapy in Structural Heart Disease Interventions Beyond TAVI

Author(s): Manolis Vavuranakis*, Konstantinos Dean Boudoulas, Ourania Katsarou, Dimitrios A. Vrachatis, Konstantinos I. Kalogeras, Theodore G. Papaioannou, Gerasimos Siasos, Evangelos Oikonomou, George Lazaros, Michael-Andreas Vavuranakis, Spyridon Deftereos, Dimitrios Tousoulis.

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 9 , 2017

Become EABM
Become Reviewer


Transcatheter interventions for structural heart disease represent an emerging field in interventional cardiology. Undoubtedly, there is an absolute necessity for antiplatelet and/or anticoagulation treatment prior, during and post such interventions. However, currently administered regimens are mainly based in expert consensus recommendations. In the present review we aim to summarize data regarding anti platelet and/or anticoagulation treatment in the following transcatheter structural heart interventions: left atrial appendage closure, atrial septal defect closure, patent foramen oval closure, paravalvular leak closure.

Keywords: ASD, LAA, PFO, transcatheter, warfarin, coumadin, antiplatelet, NOAC.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [1328 - 1333]
Pages: 6
DOI: 10.2174/1381612822666161221143416
Price: $58

Article Metrics

PDF: 35